The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Phase II GIANT trial insights: managing older adults with metastatic pancreatic cancer
Efrat Dotan, MD, Fox Chase Cancer Center, Philadelphia, PA, discusses the implications of the Phase II GIANT trial (NCT04233866) for managing vulnerable older adults with newly diagnosed metastatic pancreatic ductal adenocarcinoma (mPDAC). The GIANT trial is notable for including real-world, vulnerable patients aged 70 and older, providing valuable insights into treatment outcomes for this group. Dr Dotan highlights the importance of comprehensive baseline assessments to better understand the multifaceted factors affecting these patients. She emphasizes that improved patient selection and tailored treatment recommendations based on this evidence are crucial for optimizing care and outcomes for older adults with mPDAC. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role – Agenus; Amgen; G1 Therapeutics; Incyte; Olympus; Taiho Pharmaceutical
Research Funding – Dragonfly Therapeutics (Inst); Gilead Sciences (Inst); Ipsen (Inst); Kinnate Biopharma (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lutris (Inst); NGM Biopharmaceuticals (Inst); Relay Therapeutics (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses – Olympus
